Diagnos (ADK) AI Stock Analysis

• Market Cap: C$26.48M
• Dividend Yield: N/A
• Average Volume (3M): 193.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: -47.10%
• EPS Growth: -19.32%
• Country: CA
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 101,862,976
• 10 Day Avg. Volume: 169,187
• 30 Day Avg. Volume: 193,377
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 92.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: C$0.50 ▲(92.31% Upside)

The overall stock score is heavily impacted by Diagnos's poor financial performance, which poses significant risks to its financial health. While technical analysis indicates some short-term positive momentum, the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

Diagnos Business Overview & Revenue Model

Company Description

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.

How the Company Makes Money

Diagnos makes money through a combination of direct sales and licensing of its AI-based diagnostic platforms to healthcare providers, clinics, and hospitals. The company generates revenue by offering subscription-based access to its software tools, which are used by medical professionals for early disease detection and management. Additionally, Diagnos may engage in strategic partnerships with healthcare organizations and insurance companies to expand the reach and adoption of its technology. These partnerships can include revenue-sharing arrangements or joint ventures that contribute to its earnings.

Diagnos Financial Statement Overview

Summary

Diagnos exhibits significant financial distress across all major financial statements. The income statement shows ongoing losses, the balance sheet reveals high leverage and negative equity in some years, and cash flows highlight operational cash challenges. The company faces substantial risks that threaten its financial health, necessitating urgent strategic adjustments.

Income Statement

Diagnos has faced significant challenges in its income statement, with consistent negative gross profit margins over the years, indicating that the cost of goods sold exceeds revenue. The net profit margins are deeply negative, reflecting ongoing losses. Revenue has shown volatility, with recent declines from previous periods, further exacerbating financial instability. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet reveals financial stress with high leverage as indicated by the debt-to-equity ratio. Stockholders' equity is negative in some years, pointing to a difficult financial position. The equity ratio is low, indicating a reliance on debt financing. These factors imply potential risks in financial stability and solvency.

Cash Flow

Cash flow analysis shows persistent negative operating cash flows, indicating challenges in generating cash from operations. Free cash flow remains negative, exacerbating liquidity concerns. Financing cash flows are positive, suggesting reliance on external financing to sustain operations. Overall, cash flow management appears strained with little improvement over time.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	86.51K	103.80K	170.16K	438.83K	267.07K	331.52K
Gross Profit	-1.23M	-943.56K	35.80K	-418.30K	-347.53K	-473.45K
EBITDA	-3.98M	-3.56M	-2.45M	-2.10M	-2.45M	-1.93M
Net Income	-4.68M	-4.29M	-3.12M	-2.61M	-2.05M	-3.38M
Balance Sheet
Total Assets	2.05M	3.64M	663.79K	1.54M	1.95M	2.43M
Cash, Cash Equivalents and Short-Term Investments	1.66M	3.24M	219.01K	920.91K	1.36M	1.87M
Total Debt	2.50M	3.07M	3.19M	1.19M	471.68K	337.55K
Total Liabilities	2.85M	3.40M	3.72M	1.66M	818.19K	614.78K
Stockholders Equity	-801.73K	233.11K	-3.05M	-113.51K	1.13M	1.82M
Cash Flow
Free Cash Flow	-3.79M	-3.65M	-2.16M	-2.07M	-1.40M	-2.66M
Operating Cash Flow	-3.78M	-3.64M	-2.15M	-2.04M	-1.36M	-2.64M
Investing Cash Flow	-996.54K	-3.11M	-14.02K	503.52K	262.93K	-759.98K
Financing Cash Flow	4.75M	6.62M	2.08M	1.60M	882.82K	3.83M

Diagnos Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Positive. The current price of 0.26 is below the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.25, and below the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.32 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ADK.

Diagnos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AIML	55 Neutral	11.63M	-1.96	―	―	-72.12%	40.30%
ADK	46 Neutral	C$26.48M	―	366.78%	―	-47.10%	-19.32%
CHS	44 Neutral	10.59M	-6.03	―	―	12.44%	74.38%
UDOC	34 Underperform	13.36M	-2.22	―	―	―	21.61%
AIDR	34 Underperform	56.27M	-4.28	―	―	―	40.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Diagnos Corporate Events

Diagnos Inc. Closes $100,000 Private Placement for AI Development

Diagnos Inc. has successfully closed a non-brokered private placement, raising $100,000 through the issuance of 10 units priced at $10,000 each. The funds will be used primarily for product development, commercialization of AI-based screening services, and general administrative expenses. The transaction involved a director of the company, considered a related party, but was exempt from certain regulatory requirements due to its size. The private placement is still subject to necessary approvals, including from the TSX Venture Exchange.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

DIAGNOS Inc. Announces $100,000 Private Placement for AI Product Development

DIAGNOS Inc. announced a non-brokered private placement of 10 units at $10,000 each, totaling $100,000. The funds will primarily support product development and commercialization of AI-based screening services. A director has committed to subscribing to all units, and the placement is subject to necessary approvals.

The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.

Diagnos Inc. Extends Stock Warrants Exercise Period and Corrects Previous Announcement

Diagnos Inc. has announced its intention to extend the exercise period for 650,000 stock warrants issued as part of a non-brokered private placement, pending approval from the TSX Venture Exchange. The new expiry date is proposed to be August 5, 2026, with all other terms remaining unchanged. Additionally, Diagnos corrected a previous announcement regarding the expiry date of another set of warrants, clarifying the new date as August 5, 2026, instead of February 27, 2029. This move reflects the company’s ongoing efforts to manage its financial instruments effectively, potentially impacting investor relations and market perceptions.

Diagnos Inc. Extends Stock Warrants Exercise Period

Diagnos Inc. has announced its intention to extend the exercise period of over 1.4 million stock warrants from an initial expiry date of August 27, 2025, to February 27, 2029, pending approval from the TSX Venture Exchange. This extension is part of a strategic move to maintain favorable conditions for stakeholders, with all other warrant terms remaining unchanged. The amendment has been reviewed and approved by the board, ensuring alignment with the corporation’s and shareholders’ best interests.

DIAGNOS Advances into U.S. Optometry Market with FDA Pre-Submission for CARA System

DIAGNOS Inc. has submitted a Pre-Submission to the U.S. FDA for its CARA System, marking a strategic move into the U.S. optometry market. The CARA System is an AI-driven platform that assists optometrists in detecting retinal and systemic diseases, enhancing efficiency and consistency in eye exams. With a robust dataset from 16 countries, the system aims to improve clinical decision-making and patient outcomes, potentially reshaping the optometry landscape.

DIAGNOS Strengthens US Advisory Board with Optometry Expert Dr. Barry Ginsberg

DIAGNOS has announced the addition of Dr. Barry A. Ginsberg, a veteran optometrist, to its Scientific Advisory Board in the United States. With over three decades of experience in various optometry settings, Dr. Ginsberg’s expertise in innovative product launches and ocular disease management is expected to enhance DIAGNOS’s market strategy and demonstrate the ROI of its AI-driven screening technology. This strategic move aligns with DIAGNOS’s recent expansion into the US market, marked by the opening of a new office in South Florida, and positions the company to tap into the growing demand for eye exams in the US.